Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin

Nature Biotechnology

Volumn 34, Issue 7, 2016, Pages 738-745

  Palchaudhuri, Rahul ^a,b,c,d   Saez, Borja ^a,b,c   Hoggatt, Jonathan ^a,b,c   Schajnovitz, Amir ^a,b,c   Sykes, David B ^a,b,c   Tate, Tiffany A ^a,b,c   Czechowicz, Agnieszka ^a,c,e,f,g   Kfoury, Youmna ^a,b,c   Ruchika, F N U ^a,b,c   Rossi, Derrick J ^a,c,e,f   Verdine, Gregory L ^a,c,d   Mansour, Michael K ^h   Scadden, David T ^a,b,c  

^a Harvard University   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d HARVARD UNIVERSITY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; GRAFT VS. HOST REACTIONS; MOLECULAR BIOLOGY; PATIENT TREATMENT;

GENOTOXICITIES; GRAFT VERSUS HOST DISEASE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; IMMUNOTOXINS; RAPID RECOVERY; SICKLE-CELL ANEMIA;

STEM CELLS;

CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR ANTAGONIST; IMMUNOTOXIN; MONOCLONAL ANTIBODY ACK2; SPAONIN CONJUGATED CD45 MONOCLONAL ANTIBODY; STREPTAVIDIN; UNCLASSIFIED DRUG; CD45 ANTIGEN; MONOCLONAL ANTIBODY; PTPRC PROTEIN, MOUSE; RIBOSOME INACTIVATING PROTEIN 1; SAPORIN;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; BONE MARROW; CANDIDIASIS; CELL DEATH; CHIMERA; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HEMATOPOIETIC CELL; HEMATOPOIETIC CELL DEPLETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THYMUS ATROPHY; TRANSPLANTATION CONDITIONING; WHOLE BODY RADIATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; DNA DAMAGE; GENETIC ENHANCEMENT; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOGENETICS; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; DNA DAMAGE; FEMALE; GENETIC ENHANCEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMUNOGENETIC PHENOMENA; IMMUNOTOXINS; MICE; MICE, INBRED C57BL; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84978436680     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3584     Document Type: Article

References (69)

1. Stranges, E., Russo, C.A. & Friedman, B. in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs (Agency for Healthcare Research and Quality (AHRQ), Rockville (MD), 2006).
2. Locatelli, F. Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. Hematology 2006, 398-401 (2006).
3. Andreani, M. et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25, 401-404 (2000).
4. Andreani, M. et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 87, 3494-3499 (1996).
5. Walters, M.C. et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7, 665-673 (2001).
6. Hsieh, M.M. et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361, 2309-2317 (2009).
7. MacMillan, M.L. et al. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood 125, 3798-3804 (2015).
8. Rousso, S.Z. et al. Hematopoietic stem cell transplantations for primary immune deficiencies: 3 decades of experience from a tertiary medical center. J. Pediatr. Hematol. Oncol. 37, e295-e300 (2015).
9. Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).
10. Worth, A.J., Booth, C. & Veys, P. Stem cell transplantation for primary immune deficiency. Curr. Opin. Hematol. 20, 501-508 (2013).
11. D'Addio, F. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 63, 3041-3046 (2014).
12. Hütter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
13. Leventhal, J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra28 (2012).
14. Cartier, N. & Aubourg, P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr. Opin. Mol. Ther. 10, 471-478 (2008).
15. Booth, C., Gaspar, H.B. & Thrasher, A.J. Treating Immunodeficiency through HSC Gene Therapy. Trends Mol. Med. 22, 317-327 (2016).
16. Malech, H.L. Progress in gene therapy for chronic granulomatous disease. J. Infect. Dis. 179, (suppl. 2), S318-S325 (1999).
17. Malech, H.L., Choi, U. & Brenner, S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn. J. Infect. Dis. 57, S27-S28 (2004).
18. Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
19. van Laar, J.M. et al. Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. J. Am. Med. Assoc. 311, 2490-2498 (2014).
20. Persons, D.A. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematology (Am. Soc. Hematol. Educ. Program) 2009, 690-697 (2009).
21. Cavazzana, M. et al. Study Hgb-205: outcomes of gene therapy for hemoglobinopathies via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral βA-T87Q-globin vector (Lenti Globin® BB305 Drug Product). Blood 124, 4797 (2014).
22. Hoffman, R. Hematology: Basic Principles and Practice 5th edn. (Churchill Livingstone/Elsevier, Philadelphia, PA, 2009).
23. La Nasa, G. et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant. 36, 971-975 (2005).
24. Chen, J. et al. Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood 107, 3764-3771 (2006).
25. Czechowicz, A., Kraft, D., Weissman, I.L. & Bhattacharya, D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318, 1296-1299 (2007).
26. Xue, X. et al. Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice. Blood 116, 5419-5422 (2010).
27. Fewkes, N.M. et al. Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation. Blood 115, 4120-4129 (2010).
28. Bergamaschi, G. et al. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br. J. Haematol. 93, 789-794 (1996).
29. Pietersz, G. Cytotoxins and immunotoxins for cancer therapy: clinical applications. Immunol. Cell Biol. 83, 450 (2005).
30. Pastan, I., Hassan, R., Fitzgerald, D.J. & Kreitman, R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565 (2006).
31. Luznik, L., Jalla, S., Engstrom, L.W., Iannone, R. & Fuchs, E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98, 3456-3464 (2001).
32. Saez, B. et al. Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning. Blood 124, 2937-2947 (2014).
33. Colvin, G.A. et al. Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology. Leukemia 18, 575-583 (2004).
34. Ignatavicus, D.D. & Workman, M.L. Medical-Surgical Nursing: Patient-Centered Collaborative Care 6th edn. (Saunders Elsevier, St. Louis, MO, 2010).
35. Dominici, M. et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood 114, 2333-2343 (2009).
36. Williams, K.M. et al. Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin. Transl. Sci. 2, 279-285 (2009).
37. Ryan, T.M. et al. Human sickle hemoglobin in transgenic mice. Science 247, 566-568 (1990).
38. Iannone, R. et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood 97, 3960-3965 (2001).
39. Mikulska, M. et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 40, 271-278 (2012).
40. Marr, K.A. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology (Am. Soc. Hematol. Educ. Program) 2012, 265-270 (2012).
41. Kraft, D.L. & Weissman, I.L. Effect and kinetics of depleting ACK-2 Anti C-Kit monoclonal antibody on hematopoeisis and hematopoetic progenitors and ability to condition for bone marrow transplantation. ASH Annual Meeting Abstracts 104, 4963 (2004).
42. Derderian, S.C., Jeanty, C., Walters, M.C., Vichinsky, E. & MacKenzie, T.C. In utero hematopoietic cell transplantation for hemoglobinopathies. Front. Pharmacol. 5, 278 (2014).
43. Chandrasekaran, D., Nakamoto, B., Watts, K.L., Kiem, H.P. & Papayannopoulou, T. Modeling promising nonmyeloablative conditioning regimens in nonhuman primates. Hum. Gene Ther. 25, 1013-1022 (2014).
44. Miettinen, M. & Lasota, J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 13, 205-220 (2005).
45. Dahlke, M.H., Larsen, S.R., Rasko, J.E. & Schlitt, H.J. The biology of CD45 and its use as a therapeutic target. Leuk. Lymphoma 45, 229-236 (2004).
46. Chen, Y. et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 119, 1130-1138 (2012).
47. Pagel, J.M. et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107, 2184-2191 (2006).
48. Brenner, M.K. et al. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann. NY Acad. Sci. 996, 80-88 (2003).
49. Wulf, G.G., Luo, K.L., Goodell, M.A. & Brenner, M.K. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood 101, 2434-2439 (2003).
50. Straathof, K.C. et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 374, 912-920 (2009).
51. Dalle, J.H. HSCT for Fanconi anemia in children: factors that influence early and late results. Bone Marrow Transplant. 42 (suppl. 2), S51-S53 (2008).
52. Nakamura-Ishizu, A., Takizawa, H. & Suda, T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 141, 4656-4666 (2014).
53. Rodriguez, R., Lim, H.Y., Bartkowski, L.M. & Simons, J.W. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 34, 259-269 (1998).
54. Bouchard, H., Viskov, C. & Garcia-Echeverria, C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg. Med. Chem. Lett. 24, 5357-5363 (2014).
55. Press, O.W., Howell-Clark, J., Anderson, S. & Bernstein, I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83, 1390-1397 (1994).
56. Bikoue, A., Janossy, G. & Barnett, D. Stabilised cellular immuno-fluorescence assay: CD45 expression as a calibration standard for human leukocytes. J. Immunol. Methods 266, 19-32 (2002).
57. Weidle, U.H. et al. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics 11, 25-38 (2014).
58. Jiang, Q. et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood 112, 2858-2868 (2008).
59. Yakura, H., Shen, F.W., Bourcet, E. & Boyse, E.A. On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2. J. Exp. Med. 157, 1077-1088 (1983).
60. Jia, W., Li, W. & He, Y.-W. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 106, 3854-3859 (2005).
61. Fedeli, M. et al. Dicer-dependent microRNA pathway controls invariant NKT cell development. J. Immunol. 183, 2506-2512 (2009).
62. Kamala, T. Hock immunization: a humane alternative to mouse footpad injections. J. Immunol. Methods. 328, 204-214 (2007).
63. Sugiyama, T., Rodriguez, R.T., McLean, G.W. & Kim, S.K. HConserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc. Natl. Acad. Sci. USA 104, 175-180 (2007).
64. Schabath, R. et al. The murine chemokine receptor CXCR4 is tightly regulated during T cell development and activation. J. Leukoc. Biol 66, 996-1004 (1999).
65. Ogawa, M., ten Boekel, E. & Melchers, F. Identification of CD19(-)B220(+)c-Kit(+)Flt3/Flk-2(+)cells as early B lym phoid precursors before pre-B-I cells in juvenile mouse bone marrow. Int. Immunol 12, 313-324 (2000).
66. Dai, J. et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin. Cancer Res 20, 617-630 (2014).
67. Schmidt, M.M., Thurber, G.M. & Wittrup, K.D. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother. 57, 1879-1890 (2008).
68. Lo Celso, C. et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457, 92-96 (2009).
69. Lynch, H.E. & Sempowski, G.D. Molecular measurement of T cell receptor excision circles. Methods Mol. Biol. 979, 147-159 (2013).